1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Samsung Biologics Co.,Ltd.

Samsung Biologics Co.,Ltd.

207940.KS
Samsung Biologics Co.,Ltd.KR flagKorea Exchange
1,325,000.00
KRW
-38,000.00
- -
61.34TMarket Cap
Samsung Biologics Co.,Ltd.
207940.KS
(Korea Exchange)

Recent

price

1,325,000.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
6,097.78
2,808.08
7,896.29
10,686.45
12,319.77
16,134.19
26,782.47
36,056.87
66,161.06
79,814.81
75,548.71
- -
82,755.55
Revenue per Share
-5,561.96
59,072.39
-4,739.12
-2,230.35
5,152.94
4,666.09
5,540.89
9,050.73
17,592.49
18,528.85
23,402.83
- -
34,416.48
Basic EPS, GAAP
-39,729.06
-20,257.62
-6,186.65
-8,164.64
-7,299.72
-3,933.39
1,230.71
769.07
-1,238.39
12,117.3
6,086.2
- -
25,940.45
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-12,342.47
53,510.11
42,617.46
34,342.29
38,516.24
43,188.32
48,723.77
57,778.11
73,264.6
90,327.75
113,729.75
- -
136,635.25
Book Value per Share
18,471.19
84,925.53
109,037.16
91,021.14
95,087.12
99,635.41
105,206.02
114,032.35
66,643.22
86,378.18
115,346.29
- -
143,804.83
Tangible Book Value per Share
17
33
37
43
43
43
43
43
45
46
46
- -
55
Basic Weighted Avg Shares
105,149
91,278
294,622
464,629
535,806
701,592
1,164,777
1,568,007
3,001,295
3,694,589
3,497,146
4,556,972
4,515,818
Sales/Revenue/Turnover
-113.69
-223.1
-10.33
14.2
10.39
13.08
25.14
34.27
32.77
30.14
37.78
45.41
47.9
Operating Margin (%)
26,350
41,628
60,150
69,926
91,451
132,885
143,688
161,789
308,264
489,782
599,101
633,637
564,795
Depreciation Expense
-95,909
1,920,179
-176,823
-96,972
224,109
202,904
240,975
393,589
798,056
857,691
1,083,316
1,784,352
1,878,044
Net Income, GAAP
- -
23.44
- -
- -
26.03
- -
9.41
29.88
20.91
23.42
24.88
23.8
24.42
Effective Tax Rate (%)
-91.21
2,103.66
-60.02
-20.87
41.83
28.92
20.69
25.1
26.59
23.21
30.98
39.16
41.59
Profit Margin (%)
-19,956
-1,718,815
-1,015,120
-1,666,447
867,154
665,756
1,162,046
1,715,881
2,276,115
1,364,127
1,664,929
1,875,449
1,920,736
Working Capital
427,199
681,792
439,363
407,236
486,113
248,808
587,465
1,125,355
1,232,986
377,397
1,020,645
600,124
847,935
LT Debt
630,732
2,774,834
4,082,379
3,976,451
4,155,468
4,354,454
4,598,783
4,991,102
8,984,474
9,830,492
10,904,676
7,451,111
7,922,836
Total Equity
- -
-6.82
- -
- -
0.86
- -
5.09
6.39
8.59
7.21
8.04
14.69
14.55
Return on Invested Capital (%)
- -
142.11
- -
- -
10.28
- -
9.4
12.04
17.6
15.43
17.27
24.64
24.16
Return on Capital (%)
- -
- -
-10.62
-6.29
14.15
11.42
12.06
17
27.35
22.86
22.94
29.13
28.68
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
325,560
326,971
346,553
LT Borrowings
893,401
599,012
599,101
LT Finance Leases
2,659
1,112
248,834
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
46
46
46
Market Capitalization
83,677,609
92,524,837
82,070,507

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
6,361,638
4,408,367
4,660,750
Cash, Cash Equivalents & STI
1,960,050
1,485,083
1,652,954
Accounts Receivable, Net
- -
654,728
555,157
Inventories
3,124,830
2,128,164
2,291,556
Total Current Liabilities
3,771,311
2,532,917
2,740,014
Payables & Accruals
- -
- -
- -
ST Debt
325,560
326,971
346,553
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.66%
15.44%
-31.67%
Free Cash Flow
-147.86%
-255.88%
174.28%
Net Income, GAAP
-21.16%
52.92%
64.71%
Sales/Revenue/Turnover
56.68%
34.82%
30.31%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
946,903
1,156,904
1,187,075
1,256,439
3,497,146
2025
999,545
1,289,905
1,660,221
308,573
4,556,972
2026
1,257,119
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,874.59
6,869.71
5,713.48
- -
23,402.83
2025
8,112.04
4,557.65
12,409.76
- -
- -
2026
10,148.15
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Noxopharm Limited (NOXOF)
Sensei Biotherapeutics, Inc. (SNSE)
EvoNext Holdings S.A. (EVE.SW)
Newron Pharmaceuticals S.p.A. (NP5.DE)
Aeterna Zentaris Inc. (AEZS)
Regenicin, Inc. (RGIN)
Business
Samsung Biologics Co., Ltd. (207940.KS) operates as a leading global contract development and manufacturing organization (CDMO) providing end-to-end biologics services from cell line development and process development through clinical and commercial-scale manufacturing, aseptic fill/finish, biosafety testing, and quality assurance; core offerings encompass monoclonal antibodies, bispecific antibodies via the S-DUAL platform, antibody-drug conjugates, mRNA vaccines, and biosimilars support, with proprietary technologies including S-CHOice cell line expression and DEVELOPICK candidate selection, serving biopharmaceutical clients across oncology, immunology, inflammation, and infectious diseases. Founded in 2011 and headquartered in Songdo, Incheon, South Korea, the company maintains cGMP-compliant facilities totaling 784,000 liters capacity across five plants, including the recently operational Plant 5; it conducts operations worldwide with offices in the United States (New Jersey, San Francisco, Boston), Japan (Tokyo), and Europe, targeting top global pharmaceutical firms as clients. In November 2025, Samsung Biologics completed the spin-off of its biosimilars unit Samsung Bioepis into Samsung Epis Holdings to focus exclusively as a pure-play CDMO and address client conflict-of-interest concerns; recent major contracts include a $1.3 billion U.S. manufacturing deal in October 2025, a $1.2 billion Asia-based agreement through 2037, and a $668 million European partnership, alongside partnerships with Pfizer for biosimilars manufacturing, LigaChem Biosciences for ADC pipeline support, and Kurma Partners for development services.

Company News

APIChatGPT

  • prnewswire.com

    Samsung Biologics Releases 2026 ESG Report, Highlighting Progress in Sustainable Operations and Responsible Growth